<DOC>
	<DOCNO>NCT02467907</DOCNO>
	<brief_summary>This study assess safety define frequency severity gastrointestinal ( GI ) perforation/fistula , GI-vaginal fistula genitourinary ( GU ) fistula participant treat bevacizumab 15 milligram per kilogram ( mg/kg ) combination paclitaxel carboplatin , repeat every 3 week , recurrent , persistent metastatic cervical cancer . In addition , study include evaluation overall safety profile bevacizumab combination paclitaxel carboplatin setting , assessment GI perforation/fistula , GI-vaginal fistula GU fistula event time , evaluation efficacy .</brief_summary>
	<brief_title>Safety Efficacy Bevacizumab Combination With Carboplatin Paclitaxel Metastatic , Recurrent Persistent Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal ( &gt; =3 ) month For woman postmenopausal surgically sterile , agreement remain abstinent use single combine contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 6 month last dose study drug Distant metastatic , recurrent persistent squamous cell carcinoma , adenosquamous carcinoma adenocarcinoma cervix amenable curative treatment surgery and/or radiation therapy Either measurable nonmeasurable disease . If disease nonmeasurable limited radiation field , biopsy fineneedle aspiration require confirm malignancy Eligible carboplatin paclitaxel chemotherapy accordance local standard care Adequate hematological , renal hepatic function Normal blood coagulation parameter Recovered ( Grade less equal [ &lt; = ] 1 ) effect prior surgery , radiation therapy chemoradiotherapy Pregnant lactate History malignancy within 5 year screen , except nonmelanoma skin carcinoma Ongoing disease involve bladder rectum screening/baseline . In participant pelvic disease , absence tumor bladder rectal mucosa must demonstrate magnetic resonance imaging ( MRI ) ( preferred method , endoscopy/cystoscopy MRI easily accessible ) within 28 day enrolment Evidence abdominal free air Bilateral hydronephrosis Untreated central nervous system ( CNS ) metastases Prior chemotherapy recurrent , persistent metastatic cervical cancer . Prior adjuvant neoadjuvant chemotherapy Stage IIVA disease ( i.e . nonmetastatic disease ) permit complete great ( &gt; ) 6 month first study dose Prior chemoradiation within 3 month precede first study dose Prior radiotherapy deliver use cobalt Prior current bevacizumab antiangiogenic treatment Requirement treatment medicinal product contraindicates use study drug , may interfere plan treatment , affect participant compliance put participant high risk treatmentrelated complication Treatment another investigational agent within 28 day 2 investigational agent halflives first study dose Major surgical procedure , open biopsy significant traumatic injury within 28 day first dose bevacizumab anticipation need major surgery course study treatment Minor surgical procedure within 2 day first dose study drug Any prior history fistula GI perforation Known hypersensitivity bevacizumab excipients , Chinese hamster ovary cell product recombinant human humanize antibody plan chemotherapy Active GI bleed ulcer Uncontrolled hypertension Clinically significant active cardiovascular disease National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 4.0 , Grade great equal ( &gt; = ) 2 peripheral vascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>